Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
Braccini
G
G
Deparment of Pediatrics, University of Florence, Italy.
Lori
I
I
Neri
A S
AS
Festini
F
F
Pela
I
I
Ciuti
R
R
Boni
V
V
Zavataro
L
L
Braggion
C
C
De Martino
M
M
Taccetti
G
G
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood; D002648:Child; D003051:Cochlea / Q000187:drug effects; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D034381:Hearing Loss / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D007668:Kidney / Q000187:drug effects; D008297:Male; D014031:Tobramycin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000097:blood
D000900:Anti-Bacterial Agents; D014031:Tobramycin